Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06600789 · ClinicalTrials.gov registry record · Phase 1
A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies
A Phase 1 study of Solid Malignancies, sponsored by Carrick Therapeutics Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 6
- Study locations
NCT06600789: Recruiting Phase 1 study of Solid Malignancies, sponsored by Carrick Therapeutics Limited.
NCT06600789 is a Phase 1 study of Solid Malignancies that is actively recruiting participants, run by Carrick Therapeutics Limited. The registered enrollment target is 50 participants, below the 88-participant average among 3 other Solid Malignancies trials with a reported enrollment target (43% lower). The trial reports 6 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06600789, a Phase 1 study of Solid Malignancies, is actively recruiting participants, sponsored by Carrick Therapeutics Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 6
- Study locations
Study Summary
This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
Conditions Studied
Interventions
- DRUG CT7439 Capsules (0.5 mg, 1mg, 3mg)
Study Locations (6)
Other
- Research site 05 - Manchester
- Research site 04 - Oxford
- Research site 06 - Sutton
Texas
- Research site 03 - Dallas
- Research site 01 - San Antonio
Virginia
- Research site 02 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2026-05-22 |
| Phase | Phase 1 |
What NCT06600789 shows while recruiting
NCT06600789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 88-participant average among 3 other Solid Malignancies trials with a reported enrollment target (43% lower).
The record links to 1 condition, with Solid Malignancies appearing as the primary indexed condition, and to 1 intervention - of which CT7439 Capsules (0.5 mg, 1mg, 3mg) is the first listed.
NCT06600789 lists 6 locations in 3 states (Other, Texas, Virginia).
Frequently Asked Questions
What is clinical trial NCT06600789 about?
NCT06600789 is a clinical study titled "A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies". This modular, multi-part, multi-arm, Phase 1/2, FIH study allows the evaluation of the safety and tolerability of CT7439, dosed as a monotherapy and in combination with anticancer treatment in participants with solid malignancies.
What is the current status of trial NCT06600789?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-08-16. Estimated completion is 2026-05-22.
What conditions does trial NCT06600789 study?
This clinical trial studies the following conditions: Solid Malignancies.
What interventions are being tested in trial NCT06600789?
The interventions under investigation include: CT7439 Capsules (0.5 mg, 1mg, 3mg) (DRUG).
Who is sponsoring clinical trial NCT06600789?
This trial is sponsored by Carrick Therapeutics Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06600789 being conducted?
This trial has 6 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI